Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ARTLearn More
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized studyLearn More
CTN 331: DDI Study: Drug-drug interactions between ART and feminizing hormones in trans women living with HIV
Drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIVLearn More
Electronic capture through the Opal patient portal of a patient-reported measure of barriers to antiretroviral therapy adherence: a mixed method type 3 hybrid pilot study at a large Montreal HIV clinicLearn More
PCIRN evaluation of pandemic H1N1 (2009) influenza vaccine in adults with human immunodeficiency virus infection: Trial resultsLearn More
Predictors of antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapyLearn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.